Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: Correlations with depression and neuroleptic medication

Journal of Neurochemistry

Volumn 66, Issue 4, 1996, Pages 1592-1598

  Chen, Christopher P L H ^a,b,f   Alder, J Tracy ^a   Bowen, David M ^a   Esiri, Margaret M ^b   McDonald, Brendan ^b   Hope, Tony ^c   Jobst, Kim A ^d   Francis, Paul T ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c WARNEFORD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Alzheimer's disease; Clinicopathological correlation; Depression; Neuroleptics; Paroxetine; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CITALOPRAM; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN; SEROTONIN 1 RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RECEPTOR BINDING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; SEROTONIN RELEASE;

EID: 0029874311     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66041592.x     Document Type: Article

References (30)

1. Adolfsson R., Gottfries C. G., Roos B. E., and Winblad B. (1979) Changes in brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 135, 216-223.
2. 3H] paroxetine binding to 5-HT uptake sites in Alzheimer's disease. Neurobiol. Aging 12, 531-534.
3. 3H] paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res. 486, 261-268.
4. Bowen D. M., Allen S. J., Benton J. S., Goodhardt M. J., Haan E. A., Palmer A. M., Sims N. R., Smith C. C. T., Spillane J. A., Esiri M M., Neary D., Snowden J. S., Wilcock G. K , and Davison A N. (1983) Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem. 41, 266-272.
5. Chen C. P. L., Eastwood S. L., McDonald B., Hope R. A., Cotton R. G , and Esiri M. M. (1994) Patterns and markers of cell loss in the dorsal raphe nucleus in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 20, 503.
6. Damato R. J., Zweig R. M., Whitehouse P. J., Wenk G. L., Singer H. S., Mayeux R., Price D. L., and Snyder S. H. (1987) Aminergic systems in Alzheimers-disease and Parkinsons-disease. Ann. Neurol. 22, 229-236.
7. Folstein M. F , Folstein S., and McHugh P. R. (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198.
8. Francis P. T., Palmer A. M., Sims N. R., Bowen D. M., Davison A. N., Esiri M. M., Neary D., Snowden J. S., and Wilcock G. K. (1985) Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 313, 7-11.
9. Francis P. T., Sims N. R., Procter A. W., and Bowen D. M. (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J. Neurochem 60, 1589-1604.
10. Gottfries C. G., Karlsson I., and Nyth Å. L. (1992) Treatment of depression in elderly patients with and without dementia disorders. Int. Clin. Psychopharmacol. 6, 55-64.
11. Halliday G. M., McCann H. L., Pamphlett R., Brooks W. S., Creasey H., McCusker E., Cotton R. G. H., Broe G. A., and Harper C. G. (1992) Brain stem serotonin-synthesising neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathol. (Berl.) 84, 638-650.
12. Hope T. and Fairburn C. G. (1992) The Present Behavioral Examination (PBE) - the development of an interview to measure current behavioral abnormalities. Psychol. Med. 22, 223-230.
13. Kingsbury A. E., Foster O. J. F., Nisbet A. P., Cairns N., Bray L., Eve D. J., Lees A. J., and Marsden C. D. (1994) Tissue pH as an indicator of mRNA preservation in human postmortem brain. Mol. Brain Res. 28, 311-318.
14. Lawlor B. A., Ryan T. M., Bierer L. M., Schmeidler J., Haroutunian V., Mohs R., and Davis K. L. (1995) Lack of association between clinical symptoms and postmortem indexes of brain-serotonin function in Alzheimers-disease. Biol. Psychiatry 37, 895-896.
15. Leake A., Faibairn A. F., McKeith I. G., and Ferrier I. N. (1991) Studies on the 5-HT uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatr. Res. 39, 155-165.
16. Lebert F., Pasquier F., and Petit H. (1994) Behavioural-effects of trazodone in Alzheimers-disease. J. Clin. Psychiatry 55, 536-538.
17. McKhann G., Drachman D., Folstein M. F., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report on the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944.
18. McPherson G. A. (1985) Analysis of radioligand binding experiments: a collection of computer programs for the IBM PC. J. Pharmacol. Methods 14, 213-228.
19. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Browntee L. M., Vogel H. S., Hughes J. P., VanBelle G., and Berg L. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
20. Neary D., Snowden J. S., Mann D. M., Bowen D. M., Sims N. R , Northen B., Yates P. O., and Davison A. N. (1986) Alzheimer's disease: a correlative study. J. Neurol. Neurosurg. Psychiatry 49, 229-237.
21. Palmer A. M., Francis P. T., Benton J. S., Sims N. R., Mann D. M. A., Neary D., Snowden J. S., and Bowen D. M. (1987a) Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J. Neurochem. 48, 8-15.
22. Palmer A. M., Wilcock G. K., Esiri M. M., Francis P. T., and Bowen D. M. (1987b) Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res. 401, 231-238.
23. Palmer A. M., Stratmann G. C., Procter A. W., and Bowen D. M. (1988) Possible neurotransmitter basis of behavioural changes in Alzheimer's disease. Ann. Neurol. 23, 616-620.
24. Procter A. W., Francis P. T., Stratmann G. C., and Bowen D. M. (1992) Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochem. Res. 17, 917-922.
25. Reinikainen K. J., Paljarvi L., Huuskonen M., Soininen H., Laasko M., and Reikkinen P. (1988) A postmortem study of noradrenergic, serotonergic and GABAergic neurones in Alzheimer's disease. J. Neurol. Sci. 84, 101-116.
26. Spillane J. A. (1978) Alzheimer's Disease. A State of Cholinergic Deficiency? University of London, London.
27. Wilson M. A and Molliver M. E. (1991) The organisation of serotonergic projections to cerebral cortex in primates: retrograde transport studies. Neuroscience 44, 555-570.
28. Zhou F. C. and Azmitia E. C. (1986) Induced homotypic collateral sprouting of serotonergic fibres in the hippocampus. II. An immunocytochemical study. Brain Res. 373, 337-348.
29. Zubenko G. S., Moossy J., and Kopp U. (1990) Neurochemical correlates of major depression in primary dementia. Arch. Neurol. 47, 209-214.
30. Zweig R. M., Ross C. A., Hedreen J. C., Steele C., Cardillo J. E., Whitehouse P. J., Folstein M. F., and Price D. L. (1988) The neuropathology of aminergic nuclei in Alzheimer's disease. Ann. Neurol. 24, 233-242.